Intravitreal bevacizumab and triamcinolone treatment for choroidal neovascularization in Best disease.

Abstract

An 11-year-old girl with active subfoveal choroidal neovascularization associated with Best disease responded well to a single intravitreal injection of combined bevacizumab and triamcinolone acetonide. Choroidal neovascularization regressed, subretinal serous fluid resorbed, and visual acuity improved from 20/400 to 20/100. The patient remained stable for 6 months after injection.

• Authors: Mehmet Cakir, Osman Cekiç, O Faruk Yilmaz
• Journal: Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus (J AAPOS) Vol. 13 Issue 1 Pg. 94-6 (Feb 2009) ISSN: 1528-3933 [Electronic] United States
• PMID: 19101187 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Anti-Inflammatory Agents
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Triamcinolone
• Bevacizumab

Topics

• Angiogenesis Inhibitors (administration & dosage)
• Anti-Inflammatory Agents (administration & dosage)
• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Child
• Choroidal Neovascularization (drug therapy, etiology, pathology)
• Corneal Dystrophies, Hereditary (complications, drug therapy, pathology)
• Drug Therapy, Combination
• Female
• Humans
• Tomography, Optical Coherence
• Triamcinolone (administration & dosage)
• Vitreous Body